Nifty
:
23719.30
Sensex
:
75415.35
64.60 (0.27%)
231.99 (0.31%)
Nifty
Sensex
:
:
23719.30
75415.35
64.60 (0.27%)
231.99 (0.31%)

Dr. Reddy's Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 500124 | NSE: DRREDDY

NSE BSE
1307.20
22-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1319
  •  1329.6
  •  1305.1
  •  1318.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2002451
  •  2627152849.9
  •  1379.7
  •  1148.4

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,09,098.01
  • 26.00
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,12,042.81
  • 0.61%
  • 2.88

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.63%
  • 0.34%
  • 7.57%
  • FII
  • DII
  • Others
  • 21.14%
  • 27.83%
  • 16.49%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.69
  • 11.38
  • 9.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.08
  • 17.17
  • 6.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.37
  • 23.71
  • 7.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.76
  • 19.97
  • 19.00

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.65
  • 3.59
  • 3.39

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.24
  • 13.52
  • 11.64

Earnings Forecasts:

(Updated: 23-05-2026)
Description
2024
2025
2026
2027
Adj EPS
60.9
52.95
64.76
73.35
P/E Ratio
21.46
24.69
20.19
17.82
Revenue
34360.2
35730.3
39453.2
43404.4
EBITDA
7849.42
7375.58
8578.74
9557.23
Net Income
5091.67
4409.44
5385.63
6145.41
ROA
9.93
7.59
8.76
8.83
P/B Ratio
2.90
2.63
2.43
2.10
ROE
14.24
11.11
12.22
12.53
FCFF
3494.63
3943.98
3925.27
4200.08
FCFF Yield
3.19
3.6
3.58
3.83
Net Debt
-3527.28
-5808.57
-7459.26
-9961.69
BVPS
451.29
497.24
538.28
621.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
7,546.40
8,528.40
-11.51%
8,753.40
8,381.20
4.44%
8,828.30
8,038.20
9.83%
8,572.10
7,696.10
11.38%
Expenses
7,163.90
6,530.50
9.70%
6,865.90
6,108.20
12.40%
6,818.40
5,961.70
14.37%
6,398.50
5,566.20
14.95%
EBITDA
382.50
1,997.90
-80.85%
1,887.50
2,273.00
-16.96%
2,009.90
2,076.50
-3.21%
2,173.60
2,129.90
2.05%
EBIDTM
5.07%
23.43%
21.56%
27.12%
22.77%
25.83%
25.36%
27.68%
Other Income
475.40
522.10
-8.94%
268.80
150.20
78.96%
323.90
307.50
5.33%
290.30
187.20
55.07%
Interest
105.70
65.60
61.13%
94.40
81.70
15.54%
90.70
75.70
19.82%
83.00
59.80
38.80%
Depreciation
557.10
454.70
22.52%
521.00
471.40
10.52%
504.60
397.00
27.10%
476.10
380.60
25.09%
PBT
195.10
1,999.70
-90.24%
1,540.90
1,870.10
-17.60%
1,738.50
1,911.30
-9.04%
1,904.80
1,876.70
1.50%
Tax
-21.60
418.50
-
353.60
470.10
-24.78%
408.00
575.50
-29.11%
495.10
490.20
1.00%
PAT
216.70
1,581.20
-86.30%
1,187.30
1,400.00
-15.19%
1,330.50
1,335.80
-0.40%
1,409.70
1,386.50
1.67%
PATM
2.87%
18.54%
13.56%
16.70%
15.07%
16.62%
16.45%
18.02%
EPS
2.65
19.10
-86.13%
14.49
16.95
-14.51%
16.13
15.06
7.10%
16.98
16.70
1.68%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
33,700.20
32,643.90
28,011.10
24,669.70
21,545.20
19,047.50
17,517.00
15,448.20
14,281.00
14,196.10
15,568.30
Net Sales Growth
3.24%
16.54%
13.54%
14.50%
13.11%
8.74%
13.39%
8.17%
0.60%
-8.81%
 
Cost Of Goods Sold
12,239.20
9,979.90
8,208.70
7,657.70
7,442.20
6,078.90
5,554.40
4,494.80
4,039.50
3,696.50
3,758.50
Gross Profit
21,461.00
22,664.00
19,802.40
17,012.00
14,103.00
12,968.60
11,962.60
10,953.40
10,241.50
10,499.60
11,809.80
GP Margin
63.68%
69.43%
70.69%
68.96%
65.46%
68.09%
68.29%
70.90%
71.71%
73.96%
75.86%
Total Expenditure
27,246.70
24,096.80
20,078.00
18,320.70
17,777.80
15,177.60
15,046.60
12,270.00
11,929.80
11,723.90
11,983.00
Power & Fuel Cost
-
562.50
533.90
477.40
390.50
320.50
314.80
329.10
329.30
330.10
315.20
% Of Sales
-
1.72%
1.91%
1.94%
1.81%
1.68%
1.80%
2.13%
2.31%
2.33%
2.02%
Employee Cost
-
5,580.00
5,030.10
4,646.60
3,885.80
3,629.90
3,380.20
3,356.20
3,214.90
3,106.80
3,117.40
% Of Sales
-
17.09%
17.96%
18.84%
18.04%
19.06%
19.30%
21.73%
22.51%
21.88%
20.02%
Manufacturing Exp.
-
2,563.20
2,087.20
1,738.60
1,602.20
1,574.40
1,445.40
1,434.80
1,746.50
1,886.60
1,856.40
% Of Sales
-
7.85%
7.45%
7.05%
7.44%
8.27%
8.25%
9.29%
12.23%
13.29%
11.92%
General & Admin Exp.
-
2,016.60
1,848.20
1,497.50
1,547.60
1,251.80
1,195.20
1,132.10
1,193.40
1,339.90
1,271.40
% Of Sales
-
6.18%
6.60%
6.07%
7.18%
6.57%
6.82%
7.33%
8.36%
9.44%
8.17%
Selling & Distn. Exp.
-
3,082.10
2,248.20
1,989.40
1,919.20
1,567.70
1,408.30
1,423.50
1,330.20
1,293.40
1,181.10
% Of Sales
-
9.44%
8.03%
8.06%
8.91%
8.23%
8.04%
9.21%
9.31%
9.11%
7.59%
Miscellaneous Exp.
-
312.50
121.70
313.50
990.30
754.40
1,748.30
99.50
76.00
70.60
1,181.10
% Of Sales
-
0.96%
0.43%
1.27%
4.60%
3.96%
9.98%
0.64%
0.53%
0.50%
3.10%
EBITDA
6,453.50
8,547.10
7,933.10
6,349.00
3,767.40
3,869.90
2,470.40
3,178.20
2,351.20
2,472.20
3,585.30
EBITDA Margin
19.15%
26.18%
28.32%
25.74%
17.49%
20.32%
14.10%
20.57%
16.46%
17.41%
23.03%
Other Income
1,358.40
1,097.30
894.30
1,055.50
484.70
291.40
620.60
337.50
155.20
171.50
295.00
Interest
373.80
282.90
171.10
142.80
95.80
97.00
98.30
88.90
78.80
63.40
82.60
Depreciation
2,058.80
1,703.70
1,470.00
1,250.20
1,165.20
1,228.80
1,163.10
1,134.80
1,077.20
1,026.60
938.90
PBT
5,379.30
7,657.80
7,186.30
6,011.50
2,991.10
2,835.50
1,829.60
2,292.00
1,350.40
1,553.70
2,858.80
Tax
1,235.10
1,954.30
1,623.10
1,541.20
878.90
931.90
-140.30
385.80
438.00
296.50
751.10
Tax Rate
22.96%
25.52%
22.59%
25.64%
29.38%
32.87%
-7.67%
16.83%
32.43%
19.08%
26.27%
PAT
4,144.20
5,655.10
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
2,107.70
PAT before Minority Interest
4,182.60
5,725.20
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
2,107.70
Minority Interest
38.40
-70.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.30%
17.32%
19.91%
18.27%
10.13%
10.25%
11.57%
12.62%
6.39%
8.86%
13.54%
PAT Growth
-27.34%
1.38%
23.75%
106.52%
11.83%
-3.67%
3.90%
113.72%
-27.43%
-40.35%
 
EPS
56.38
76.94
75.89
61.32
29.69
26.55
27.56
26.53
12.41
17.10
28.68

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
33,549.60
28,254.80
23,286.10
19,212.40
17,641.70
15,598.80
14,023.60
12,571.60
12,262.10
12,569.80
Share Capital
83.40
83.40
83.30
83.20
83.20
83.10
83.00
83.00
82.90
85.30
Total Reserves
33,321.50
28,040.10
23,057.10
18,985.90
17,431.90
15,411.90
13,861.10
12,406.00
12,098.80
12,393.90
Non-Current Liabilities
632.90
-36.80
-278.30
-508.30
-197.30
-807.50
2,113.00
2,538.40
456.10
876.70
Secured Loans
406.40
219.00
127.80
194.60
249.90
130.40
55.20
63.00
59.70
74.70
Unsecured Loans
380.00
380.00
0.00
380.00
380.00
0.00
2,144.80
2,445.90
485.20
993.80
Long Term Provisions
29.80
23.90
19.90
25.80
50.80
74.50
79.30
81.70
84.20
95.20
Current Liabilities
13,033.80
9,588.00
8,572.10
9,765.80
8,103.80
7,214.10
5,897.30
6,893.80
8,419.90
6,347.10
Trade Payables
2,647.80
2,614.40
2,268.40
2,266.20
1,810.90
1,524.80
1,367.10
1,334.50
1,056.90
906.80
Other Current Liabilities
5,503.10
4,775.20
4,697.90
3,660.60
3,338.10
3,512.00
2,820.70
2,411.40
2,339.70
2,409.10
Short Term Borrowings
3,804.50
1,272.30
739.00
2,708.20
2,314.50
1,653.20
1,212.50
2,556.20
4,362.60
2,271.80
Short Term Provisions
1,078.40
926.10
866.80
1,130.80
640.30
524.10
497.00
591.70
660.70
759.40
Total Liabilities
47,594.10
37,806.00
31,579.90
28,469.90
25,548.20
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
Net Block
18,226.40
10,425.60
9,219.10
8,121.50
8,205.70
6,850.30
7,191.00
6,968.00
6,930.70
6,563.00
Gross Block
33,145.70
24,527.40
25,567.10
23,096.40
21,886.70
19,335.50
18,048.40
17,436.30
15,932.40
15,019.70
Accumulated Depreciation
14,754.40
14,101.30
16,348.00
14,894.90
13,632.10
12,485.20
10,857.40
10,468.30
9,001.70
8,456.70
Non Current Assets
22,576.00
13,000.70
11,154.50
10,682.00
10,997.90
9,406.30
10,923.80
11,505.40
11,454.40
7,999.60
Capital Work in Progress
2,465.60
1,419.30
1,030.10
1,293.40
1,565.10
1,535.10
2,933.50
3,470.50
3,324.50
772.20
Non Current Investment
720.40
525.50
536.30
593.00
833.30
309.10
334.20
465.30
682.60
329.70
Long Term Loans & Adv.
341.40
541.80
355.90
451.70
377.00
688.70
426.70
564.80
482.10
290.40
Other Non Current Assets
822.20
88.50
13.10
222.40
16.80
23.10
38.40
36.80
34.50
44.30
Current Assets
25,018.10
24,805.30
20,425.40
17,787.90
14,535.20
12,599.10
11,110.10
10,498.40
9,683.70
11,794.00
Current Investments
3,330.60
4,405.00
4,449.50
2,022.90
1,378.50
2,368.70
2,252.90
1,833.00
1,427.10
3,503.40
Inventories
7,108.50
6,355.20
4,867.00
5,088.40
4,541.20
3,506.70
3,357.90
2,908.90
2,852.80
2,557.90
Sundry Debtors
9,042.00
8,029.80
7,248.50
6,676.40
4,964.10
5,027.80
3,986.90
4,052.70
3,798.60
4,125.00
Cash & Bank
2,460.20
1,727.70
1,730.20
2,419.20
2,078.80
205.30
222.80
263.80
386.50
492.10
Other Current Assets
3,076.80
1,011.30
1,203.50
736.90
1,572.60
1,490.60
1,289.60
1,440.00
1,218.70
1,115.60
Short Term Loans & Adv.
2,004.30
3,276.30
926.70
844.10
722.70
444.50
439.80
674.10
767.20
722.50
Net Current Assets
11,984.30
15,217.30
11,853.30
8,022.10
6,431.40
5,385.00
5,212.80
3,604.60
1,263.80
5,446.90
Total Assets
47,594.10
37,806.00
31,579.90
28,469.90
25,533.10
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
4,642.80
4,543.30
5,887.50
2,810.80
3,570.30
2,984.10
2,870.40
1,803.00
2,144.40
3,262.60
PBT
7,679.50
7,201.00
6,048.50
3,061.40
2,883.50
1,885.70
2,335.80
1,350.40
1,553.70
2,858.80
Adjustment
1,961.50
1,365.20
1,695.90
2,333.80
2,087.20
2,562.50
835.00
1,625.30
1,687.30
1,107.70
Changes in Working Capital
-2,998.90
-2,018.20
-785.50
-1,840.70
-828.80
-753.60
183.70
-896.60
-519.60
-2.50
Cash after chg. in Working capital
6,642.10
6,548.00
6,958.90
3,554.50
4,141.90
3,694.60
3,354.50
2,079.10
2,721.40
3,964.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,999.30
-2,004.70
-1,071.40
-743.70
-571.60
-710.50
-484.10
-276.10
-577.00
-701.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,807.70
-4,028.30
-4,137.30
-2,638.70
-2,266.00
-492.30
-772.70
-1,488.30
-1,840.40
-2,039.40
Net Fixed Assets
-2,403.40
-1,447.20
-1,511.60
-1,303.60
-2,618.10
-453.50
-275.60
-683.20
-1,019.30
-1,892.20
Net Investments
-5,872.90
119.40
-2,503.30
-287.50
836.30
-1,552.00
-297.00
-534.60
1,974.20
-1,213.80
Others
2,468.60
-2,700.50
-122.40
-1,047.60
-484.20
1,513.20
-200.10
-270.50
-2,795.30
1,066.60
Cash from Financing Activity
1,891.10
-376.30
-2,686.10
-242.20
-29.80
-2,515.90
-2,132.60
-444.00
-369.20
-1,700.10
Net Cash Inflow / Outflow
726.20
138.70
-935.90
-70.10
1,274.50
-24.10
-34.90
-129.30
-65.20
-476.90
Opening Cash & Equivalents
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10
539.50
Closing Cash & Equivalent
1,459.30
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
400.54
337.21
277.80
1145.98
1052.59
932.31
840.01
752.35
734.72
731.49
ROA
13.41%
16.08%
15.01%
8.08%
8.01%
8.95%
8.66%
4.23%
6.14%
11.05%
ROE
18.61%
21.76%
21.36%
11.93%
11.53%
13.38%
14.42%
7.40%
10.20%
18.95%
ROCE
23.25%
26.86%
26.22%
14.59%
15.24%
10.81%
13.41%
8.21%
9.77%
19.55%
Fixed Asset Turnover
1.13
1.12
1.01
0.96
0.92
0.94
0.87
0.86
0.92
1.13
Receivable days
95.44
99.54
103.01
98.60
95.74
93.92
94.98
100.33
101.86
96.43
Inventory Days
75.27
73.12
73.65
81.57
77.11
71.52
74.03
73.63
69.56
60.11
Payable days
96.23
108.56
108.07
99.98
100.14
39.56
39.46
37.10
31.00
28.67
Cash Conversion Cycle
74.48
64.10
68.59
80.19
72.70
125.88
129.55
136.86
140.42
127.87
Total Debt/Equity
0.14
0.07
0.06
0.18
0.17
0.14
0.28
0.41
0.40
0.27
Interest Cover
28.15
43.09
43.36
32.96
30.23
19.61
26.78
18.14
25.51
35.61

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Dr. Reddy's Laboratories launches generic Semaglutide Injection in Canada
    16th May 2026, 11:47 AM

    The company’s Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus

    Read More
  • Dr. Reddy's Laboratories reports 86% plunge in Q4FY26 consolidated net profit
    13th May 2026, 12:12 PM

    Consolidated total income of the company decreased by 11.37% at Rs 8,021.80 crore for Q4FY26

    Read More
  • Dr. Reddy's Lab - Quarterly Results
    13th May 2026, 00:00 AM

    Read More
  • Dr. Reddy's Lab gets Health Canada’s nod for Generic Semaglutide Injection
    29th Apr 2026, 10:51 AM

    The company becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada

    Read More
  • Dr. Reddy's Laboratories to sell entire shareholding in Svaas Wellness
    8th Apr 2026, 16:00 PM

    Consequent to the completion of the transaction, Svaas Wellness will cease to be a wholly owned subsidiary of the Company

    Read More
  • Dr. Reddy’s Laboratories launches Semaglutide injection ‘Obeda’ for Type 2 Diabetes
    21st Mar 2026, 16:06 PM

    The company has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide

    Read More
  • Dr. Reddy's Laboratories gets EIR for Andhra Pradesh’s manufacturing facility
    6th Mar 2026, 10:23 AM

    USFDA has classified the inspection outcome as Voluntary Action Indicated

    Read More
  • Dr. Reddy's acquires specialty brands Progynova, Cyclo-Progynova in India
    19th Feb 2026, 10:22 AM

    The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.